Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by josameyeron Dec 19, 2011 8:37am
352 Views
Post# 19333972

as we wait for sanity to return in trading

as we wait for sanity to return in tradingEverton, revised option  agreement to purchase the 3 properties in the Dominican Republic which is due December 31,2011. The 3 properties consist of, one Ampliacion Pueblo Viejo, two Ponton and last Cueva. Everton  is to issue 15 million treasury common shares to acquire the option.Pursuant  to the option, Everton can acquire Brigus remaining interest in the consessions by paying Brigus CAD $500000 and a additional CAD $500000 in cash  or common shares with a value of $500000.Plus a sliding scale Royalty. In addition a 5 million dollar promissory note subject to the completion of a material instument 43-101 compliant measuring 1 million ounces of gold at  certain grades.I believe Everton trades currently at 12 cents.I believe the revision took place near the end of September 2011.The  foregoing might be of interest of some.Please DYODD.Have a great day ,Josa.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse